Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 5/20 | 0.56 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | LAP3 | P28838 | 1/20 | 0.39 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6445282 | 0.76 | FDPS (0.54) | LAP3 | |
| SCHEMBL341289 | 0.71 | — | — | |
| SCHEMBL341418 | 0.71 | — | — | |
| SCHEMBL6424687 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL8971868 | 0.70 | GABBR2 (0.58) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL27537883 | 0.68 | GABBR2 (0.45) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL10587263 | 0.67 | GABBR2 (0.54) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| Propylamine SCHEMBL21271949 | 0.66 | — | — | |
| SCHEMBL19455938 | 0.66 | LAP3 (0.46) | LAP3METAP1 | |
| SCHEMBL316162 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190167632-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | MUELLER WOLFGANG S (US) | 2019-06-06 | — | — | US | claimed |
| US-10238622-B2 | Methods of treating and preventing/reducing the likelihood of Mesial temporal lobe epilepsy (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2019-03-26 | — | — | US | claimed |
| EP-2593104-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | Müller, Prof. Dr., Wolfgang (DE) | 2013-05-22 | — | — | EP | claimed |
| US-20120115919-A1 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | THE REGENTS OF THE UNIVERSITY OF NEW MEXICO | 2012-05-10 | — | — | US | claimed |
| WO-2011113904-A1 | MEDICAMENTS FOR THE PREVENTION AND TREATMENT OF A DISEASE ASSOCIATED WITH RETINAL GANGLION CELL DEGENERATION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2011-09-22 | — | — | WO | claimed |
| WO-2011011692-A2 | METHODS OF TREATING AND PREVENTING/REDUCING THE LIKELIHOOD OF MESIAL TEMPORAL LOBE EPILEPSY (TLE) | STC.UNM (US) | 2011-01-27 | — | — | WO | claimed |
| WO-2009121496-A2 | USE OF A BIOLOGICALLY ACTIVE BLOOD SERUM FOR THE TREATMENT OF A DISORDER CHARCTERIZED IN A REDUCED FUNCTION OF A GABA RECEPTOR | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | WO | claimed |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | OWEN HOLDING LTD. (GB) | 2009-10-08 | — | — | US | claimed |
| EP-2106799-A1 | Use of a biologically active blood serum for the treatment of a disorder characterized in a reduced function of a GABA receptor | OWEN Holding LTD (GB) | 2009-10-07 | — | — | EP | claimed |
| US-20080318908-A1 | USE OF GABA AND GABAB AGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2008-12-25 | — | — | US | claimed |
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| EP-1644043-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA Pharma AG (DE) | 2006-04-12 | — | — | EP | claimed |
| WO-2005037215-A2 | COMPOSITIONS AND METHODS FOR ENHANCING COGNITIVE FUNCTION AND SYNAPTIC PLASTICITY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2005-04-28 | — | — | WO | claimed |
| WO-2004105795-A1 | PHARMACEUTICAL COMBINATIONS OF A PROTON PUMP INHIBITOR AND A COMPOUND WHICH MODIFIES GASTROINTESTINAL MOTILITY | ALTANA PHARMA AG (DE) | 2004-12-09 | — | — | WO | claimed |
| EP-0936906-B1 | REFLUX INHIBITORS | ASTRAZENECA AB (SE) | 2003-09-10 | — | — | EP | claimed |
| US-20030162754-A1 | Use of GABA and GABAB agonists | TUFTS UNIVERSITY | 2003-08-28 | — | — | US | claimed |
| US-6117908-A | Use of GABAB receptor agonists as reflux inhibitors | ASTRA AKTIEBOLAG (SE) | 2000-09-12 | — | — | US | claimed |
| US-5567840-A | AS 4-AMINOBUTYRIC ACID AGONIST; MUSCLE RELAXANTS | CIBA-GEIGY CORPORATION (US) | 1996-10-22 | — | — | US | claimed |
| EP-0399949-B1 | Substituted aminoalkylphosphinic acids | CIBA GEIGY AG (CH) | 1995-04-12 | — | — | EP | claimed |
| EP-0399949-A1 | Substituted aminoalkylphosphinic acids | CIBA-GEIGY AG (CH) | 1990-11-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089335-A1 | Compositions and methods for enhancing cognitive function and synaptic plasticity | GRIN2B, CACNA1B, GRIN2A | GABBR2 63/4885GABBR1 54/4885CYP1A2 4196/4885 |
| US-20090252786-A1 | Use of a Biologically Active Blood Serum for the Treatment of a Disorder Characterized in a Reduced Function of a GABA Receptor | GABBR1, GABBR2, GABRA2 | GABBR2 2/4885GABBR1 1/4885CYP1A2 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.